The effects of alternative treatments for HIV disease on recommended pharmacological regimens

Citation
R. Manfredi et F. Chiodo, The effects of alternative treatments for HIV disease on recommended pharmacological regimens, INT J ANT A, 13(4), 2000, pp. 281-285
Citations number
24
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Microbiology
Journal title
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
ISSN journal
0924-8579 → ACNP
Volume
13
Issue
4
Year of publication
2000
Pages
281 - 285
Database
ISI
SICI code
0924-8579(2000)13:4<281:TEOATF>2.0.ZU;2-N
Abstract
The use of alternative treatments for HIV disease was assessed before and a fter the introduction of highly active antiretroviral therapy (HAART) by th e use of a standardised questionnaire. These data were related to epidemiol ogical, clinical and laboratory parameters and compliance levels to recomme nded antiretroviral and anti-Pneumocystis carinii regimens. Compared with t he 476 evaluable patients interviewed during the first 9 months of 1996, th e 549 evaluable subjects screened in January-September 1998 showed less fre quent recourse to alternative treatments (22.8 vs. 35.7% of patients; P < 0 .001). A significant correlation between use of alternatives, pour complian ce to antiretroviral drugs and anti-P. carinii chemoprophylaxis and clinica l and immunological progression of HIV disease was shown in 1996, but was n ot maintained in 1998. No relevant differences were found in the selection of most non-conventional treatments and in the number of strategies followe d and their duration of use. Unorthodox treatments were used by most patien ts concurrently rather than instead of official therapeutic regimens. No co rrelation was found between the use of alternative treatment and the patien ts' age, gender, type of risk for HIV disease and duration of HIV seroposit ivity. The correlations between alternative and official treatments for HIV disease before and during the HAART era shows that a considerable percenta ge of patients still resort to alternatives in 1998 compared with 1996 but that this does not interfere with compliance with recommended pharmacologic al regimens or the progression of the disease. (C) 2000 Published by Elsevi er Science B.V. and International Society of Chemotherapy. All rights reser ved.